Bio-Rad Laboratories (BIO.B) vs iRhythm (IRTC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Bio-Rad Laboratories (BIO.B) has outperformed iRhythm (IRTC) over the past year, gaining 28.2% versus a loss of 39.6%. Over five years, IRTC leads with a +47.6% price change compared with -50.5% for BIO.B. Bio-Rad Laboratories is the larger company by market cap ($9.76 billion vs $3.52 billion), about 2.8 times the size, while iRhythm is growing revenue faster (+26.2% vs +0.7%).
Bio-Rad Laboratories converts more of its revenue into profit, with a net margin of 29.4% versus -6.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIO.B | IRTC |
|---|---|---|
| Share price | $365.08 | $106.70 |
| Market cap | $9.76B | $3.52B |
| 1-day change | 0.00% | +4.00% |
| YTD return | +17.50% | -39.87% |
| 1-year return | +28.15% | -39.57% |
| 5-year return | -50.54% | +47.60% |
| P/E ratio (TTM) | 46.27 | — |
| Forward P/E | — | 83.26 |
| EPS (TTM) | $7.89 | $-0.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.58B | $747.14M |
| Revenue growth (YoY) | +0.65% | +26.24% |
| Net income (latest FY) | $759.90M | $-44.55M |
| Gross margin | 51.87% | 70.57% |
| Operating margin | 1.83% | -7.68% |
| Net margin | 29.42% | -5.96% |
| 52-week high | $365.08 | $212.00 |
| 52-week low | $244.54 | $100.70 |
| Distance from 52-week high | 0.00% | -49.67% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +63.01% |
| Average volume | 4 | 568.57K |
| Shares outstanding | 5.06M | 32.96M |
| Employees | 7,450 | 2,400 |
| Sector | Healthcare | Health Care |
| Industry | Medical Devices | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Bio-Rad Laboratories is about 2.8 times larger than iRhythm by market value ($9.76B vs $3.52B).
- BIO.B has outperformed IRTC by 67.7 percentage points over the past year.
- Bio-Rad Laboratories is more profitable, keeping 29.4 cents of every revenue dollar as net income versus -6.0 cents for iRhythm.
- iRhythm grew revenue faster in its latest fiscal year (+26.24% vs +0.65%).
- The two companies sit in different sectors: Bio-Rad Laboratories in Healthcare and iRhythm in Health Care.
About Bio-Rad Laboratories
BIO.B stock →Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally.
Healthcare · Medical Devices · 7,450 employees
About iRhythm
IRTC stock →iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services.
Health Care · Medical/Dental Instruments · 2,400 employees
BIO.B vs IRTC FAQ
Which is bigger, Bio-Rad Laboratories or iRhythm?
Bio-Rad Laboratories (BIO.B) is larger, with a market capitalization of $9.76B compared with $3.52B for iRhythm (IRTC).
Which stock has performed better over the past year, BIO.B or IRTC?
BIO.B returned +28.15% over the past 12 months, compared with -39.57% for IRTC (price return, excluding dividends). Past performance does not predict future results.
Are Bio-Rad Laboratories and iRhythm in the same industry?
No. Bio-Rad Laboratories is in the Healthcare sector, while iRhythm is in Health Care.